天士力：PD-L1/VEGF双抗的实体瘤适应症IIa期、直肠癌适应症IIb期临床试验正在入组中

Core Viewpoint - Tianjin Tasly Pharmaceutical Group is advancing its clinical trials for PD-L1/VEGF dual antibody in solid tumors and for rectal cancer, indicating ongoing development in innovative cancer therapies [2] Group 1: Clinical Trials - The company is currently enrolling participants for the Phase IIa clinical trial of PD-L1/VEGF dual antibody for solid tumor indications [2] - The Phase IIb clinical trial for rectal cancer is also in the participant enrollment stage [2] - The clinical trial for recombinant human fibroblast growth factor 21 injection has progressed to Phase Ib [2] Group 2: Future Announcements - The company will disclose further research and development progress in accordance with relevant information disclosure regulations [2]